The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors

Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

(2013) Stephan A. Veltkamp et al.   CLINICAL DRUG INVESTIGATION

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus

(2013) Muhammad Abdul-Ghani et al.   Endocrine Practice

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

(2012) Masakazu Imamura et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Glycemic Response and Attainment of A1C Goals Following Newly Initiated Insulin Therapy for Type 2 Diabetes

(2012) G. A. Nichols et al.   DIABETES CARE

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Minireview: Epigenetics of Obesity and Diabetes in Humans

(2012) Howard Slomko et al.   ENDOCRINOLOGY

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

(2012) Vivian A. Fonseca et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass

(2011) Juris J. Meier et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma

(2011) Bingquan Lai et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Genotyping analysis of Helicobacter pylori using multiple-locus variable-number tandem-repeats analysis in five regions of China and Japan

(2011) Chunliang Guo et al.   BMC MICROBIOLOGY

Diabetes mellitus: new drugs for a new epidemic

(2011) G. Nicholson et al.   BRITISH JOURNAL OF ANAESTHESIA

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

(2011) K Yamamoto et al.   BRITISH JOURNAL OF PHARMACOLOGY

Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study

(2011) Sreeneeranj Kasichayanula et al.   CLINICAL THERAPEUTICS

Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’

(2011) Timothy C. Hardman et al.   CURRENT PHARMACEUTICAL DESIGN

Standards of Medical Care in Diabetes--2012

(2011)   DIABETES CARE

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

(2011) L. Thomas et al.   DIABETES OBESITY & METABOLISM

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

(2011) R. L. Dobbins et al.   DIABETES OBESITY & METABOLISM

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

(2011) Sherwyn L. Schwartz et al.   Diabetes Technology & Therapeutics

Dapagliflozin—redefining treatment of T2DM?

(2011) Edward C. Chao   Nature Reviews Endocrinology

Understanding type 1 diabetes through genetics: advances and prospects

(2011) Constantin Polychronakos et al.   NATURE REVIEWS GENETICS

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

(2011) Atsuo Tahara et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study

(2011) Glenn F. Carlson et al.   Diabetes Therapy

The Stunned β Cell: A Brief History

(2010) Ele Ferrannini   Cell Metabolism

Sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2010) Volker Vallon et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for New Anti-Diabetic Agent

(2010) Sumihiro Nomura   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Sodium-Glucose Co-Transport Inhibitors

(2010) Joshua J. Neumiller et al.   DRUGS

Dapagliflozin: more than just another oral glucose-lowering agent?

(2010) Niki Katsiki et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study

(2010) Elizabeth K. Hussey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

(2010) Elizabeth K. Hussey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of Canagliflozin, a NovelC-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus(1)

(2010) Sumihiro Nomura et al.   JOURNAL OF MEDICINAL CHEMISTRY

(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment

(2010) Hiroyuki Kakinuma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dapagliflozin, an SGLT2 inhibitor, for diabetes

(2010) Markolf Hanefeld et al.   LANCET

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Phloridzin: Biosynthesis, distribution and physiological relevance in plants

(2010) Christian Gosch et al.   PHYTOCHEMISTRY

Molecular Mechanism of Insulin Resistance in Obesity and Type 2 Diabetes

(2010) Kangduk Choi et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Glucose Control by the Kidney: An Emerging Target in Diabetes

(2009) Olivera Marsenic   AMERICAN JOURNAL OF KIDNEY DISEASES

Dapagliflozin for the Treatment of Type 2 Diabetes

(2009) Amie McCord Brooks et al.   ANNALS OF PHARMACOTHERAPY

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

(2009) M. Obermeier et al.   DRUG METABOLISM AND DISPOSITION

Dapagliflozin: an emerging treatment option in type 2 diabetes

(2009) Mark Kipnes   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dapagliflozin: where does it fit in the treatment of type 2 diabetes?

(2009) Vincent C Woo   EXPERT OPINION ON PHARMACOTHERAPY

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Autoantibodies in type 1 diabetes

(2008) Craig E. Taplin et al.   AUTOIMMUNITY

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

(2008) Zhang Weihua et al.   CANCER CELL

Expression of SGLT1, Bcl-2 and p53 in Primary Pancreatic Cancer Related to Survival

(2008) Veerle F. Casneuf et al.   CANCER INVESTIGATION

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

(2008) S. A. Jabbour et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2008) Wei Meng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

(2008) Y. Fujimori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE